JMP Securities Lowers Ariad Pharmaceuticals Price Target to $30.00 (ARIA)
Investment analysts at JMP Securities decreased their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) to $30.00 in a note issued to investors on Monday, American Banking and Market News reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price objective would suggest a potential upside of 63.04% from the company’s current price.
A number of other analysts have also recently weighed in on ARIA. Analysts at Brean Capital cut their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $28.00 to $26.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Maxim Group cut their price target on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from $26.00 to $24.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Oppenheimer upgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. They now have a $24.00 price target on the stock, up previously from $23.00. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.72.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 1.55% on Monday, hitting $18.40. The stock had a trading volume of 7,593,465 shares. Ariad Pharmaceuticals has a 1-year low of $15.35 and a 1-year high of $25.40. The stock’s 50-day moving average is $19.47 and its 200-day moving average is $18.64. The company’s market cap is $3.406 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was up 4302.5% on a year-over-year basis. On average, analysts predict that Ariad Pharmaceuticals will post $-1.63 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.